Sodium-Glucose Cotransporter 2 Inhibitor [EPC]: Side Effects & Safety Data for 4 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Sodium-Glucose Cotransporter 2 Inhibitor [EPC] includes 4 drugs with a combined 78,815 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
4
Drugs in Class
78,815
Combined Reports
All Sodium-Glucose Cotransporter 2 Inhibitor [EPC] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| EMPAGLIFLOZIN | Jardiance | 37,059 | 1,624 | 12,216 | 4.4% |
| CANAGLIFLOZIN | INVOKANA | 24,411 | 544 | 9,503 | 2.2% |
| DAPAGLIFLOZIN PROPANEDIOL | FARXIGA | 16,873 | 3,694 | 2,425 | 21.9% |
| SOTAGLIFLOZIN | INPEFA | 472 | 26 | 82 | 5.5% |
Common Side Effects in Sodium-Glucose Cotransporter 2 Inhibitor [EPC] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Diabetic ketoacidosis | 7,604 | 157 |
| Fungal infection | 4,546 | 14 |
| Death | 4,392 | 4,385 |
| Weight decreased | 3,461 | 49 |
| Blood glucose increased | 3,360 | 17 |
| Acute kidney injury | 3,118 | 152 |
| Urinary tract infection | 2,963 | 67 |
| Dizziness | 2,626 | 26 |
| Nausea | 2,387 | 34 |
| Toe amputation | 2,369 | 20 |